Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The von Hippel-Lindau gene (VHL) alteration, a common event in sporadic clear-cell renal-cell carcinoma (CCRCC), leads to highly vascularised tumours. Vascular endothelial growth factor (VEGF) is the major factor involved in angiogenesis, but the prognostic significance of both VHL inactivation and VEGF expression remain controversial. The aims of this study were to analyse the relationship between VHL genetic and epigenetic alterations, VHL expression and VEGF tumour or plasma expression, and to analyse their respective prognostic value in patients with CCRCC. METHODS: A total of 102 patients with CCRCC were prospectively analysed. Alterations in VHL were determined by sequencing, Multiplex Ligation-dependent Probe Amplification (MLPA) and methylation-specific MLPA. Expression of pVHL and VEGF was determined by immunohistochemistry. Plasma VEGF was measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: VHL mutation, deletion and promoter methylation were identified in 70, 76 and 14 cases, respectively. Overall, at least one VHL-gene alteration occurred in 91 cases (89.2%). Both VEGF tumour and plasma expression appeared to be decreased in case of VHL alteration. Median progression-free survival and CCRCC-specific survival were significantly reduced in patients with wild-type VHL or altered VHL and high VEGF expression, which, therefore, represent two markers of tumour aggressiveness in CCRCC. CONCLUSION: Stratifying CCRCCs according to VHL and VEGF status may help tailor therapeutic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“…to note that the survival of patients with poor prognostic metastatic RCC according to the Memorial Sloan-Kettering Hospital Cancer Center (MSKCC) classification is increased by using mTOR inhibitors that do not target specifically the VHL/VEGF pathway (Hudes et al, 2007; Motzer et al, 2008).”
BackgroundMutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730 · cited 1×
“It is generally believed that this overexpression is due to VHL inactivation that occurs with a high frequency in sporadic CCRCC (70– 80%; Gnarra et al, 1994; Yao et al, 2002).”
Background(2006) · New England Journal of Medicine · doi:10.1056/nejmc052564 · Cited by 189
Cited by
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Moore, L. E., Nickerson, M. L., Brennan, P., Toro, J. R., Jaeger, E., Rinsky, J., Han, S. S., Zaridze, D., Matveev, V., Janout, V., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002312 · Cited by 199
ROTS: reproducible RNA-seq biomarker detector—prognostic markers for clear cell renal cell cancer
Seyednasrollah, F., Rantanen, K., Jaakkola, P., & Elo, L. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv806 · Cited by 75
“Although studies attempting to correlate VHL mutation with patient prognosis have been somewhat conflicting, correlation of wild-type VHL with poor prognosis has been reported earlier (38,39).”
BackgroundWohlrab, C., Vissers, M. C. M., Phillips, E., Morrin, H., Robinson, B. A., & Dachs, G. U. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00574 · Cited by 35
Metadata
- Authors
- Patard, J.-J., Rioux-Leclercq, N., Masson, D., Zerrouki, S., Jouan, F., Collet, N., Dubourg, C., Lobel, B., Denis, M., & Fergelot, P.
- Venue
- British Journal of Cancer
- Published
- 2009-09-15
- Volume
- 101
- Issue
- 8
- Pages
- 1417-1424
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2038781838
- Cited by
- 99
- References
- 3
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6605298
- The paper
- Patard, J.-J., Rioux-Leclercq, N., Masson, D., Zerrouki, S., Jouan, F., Collet, N., Dubourg, C., Lobel, B., Denis, M., & Fergelot, P. (2009). Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.